Senzime AB Asset Resilience Ratio
Senzime AB asset resilience ratio. Senzime AB (SEZI) has an Asset Resilience Ratio of 20.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Senzime AB to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Senzime AB (2016–2025)
Asset resilience ratio of Senzime AB from 2016 to 2025. This chart shows how Senzime AB's Asset Resilience Ratio has changed over time. Read SEZI total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Senzime AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Senzime AB (SEZI) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr73.97 Million | 20.0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr73.97 Million | 20.00% |
Asset Resilience Insights
- Good Liquidity Position: Senzime AB maintains a healthy 20.00% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Senzime AB Industry Peers by Asset Resilience Ratio
Compare Senzime AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Senzime AB Asset Resilience Ratio by Year (2016–2025)
Senzime AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Senzime AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.00% | Skr73.97 Million ≈ $7.96 Million |
Skr369.81 Million ≈ $39.80 Million |
-3.67pp |
| 2024-12-31 | 23.67% | Skr100.94 Million ≈ $10.86 Million |
Skr426.36 Million ≈ $45.88 Million |
-11.16pp |
| 2023-12-31 | 34.83% | Skr151.01 Million ≈ $16.25 Million |
Skr433.54 Million ≈ $46.66 Million |
+26.76pp |
| 2022-12-31 | 8.07% | Skr26.04 Million ≈ $2.80 Million |
Skr322.68 Million ≈ $34.73 Million |
-34.81pp |
| 2021-12-31 | 42.88% | Skr74.87 Million ≈ $8.06 Million |
Skr174.62 Million ≈ $18.79 Million |
-19.04pp |
| 2020-12-31 | 61.92% | Skr160.31 Million ≈ $17.25 Million |
Skr258.89 Million ≈ $27.86 Million |
+45.47pp |
| 2019-12-31 | 16.46% | Skr30.90 Million ≈ $3.33 Million |
Skr187.76 Million ≈ $20.21 Million |
-0.11pp |
| 2018-12-31 | 16.57% | Skr32.67 Million ≈ $3.52 Million |
Skr197.16 Million ≈ $21.22 Million |
+11.31pp |
| 2017-12-31 | 5.26% | Skr8.74 Million ≈ $940.35K |
Skr166.03 Million ≈ $17.87 Million |
-1.15pp |
| 2016-12-31 | 6.41% | Skr10.03 Million ≈ $1.08 Million |
Skr156.31 Million ≈ $16.82 Million |
-- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more